论文部分内容阅读
医药企业和患者集团对医药分业有强烈的制度偏好,是推动改革的主导力量。但由于其在制度体系中的地位以及自身特点等原因,对政策制定的影响力较弱。而处于政策制定核心地位的中央部门,由于过于强调争取和维护本部门利益,对医药分业制度安排难以达成一致意见,无法形成统一的方案,致使我国的医药分业改革进程陷入停滞。要推进改革,实现彻底的医药分业,需要协调各集团的利益,并构建各集团能够实现有序博弈的制度平台。
Pharmaceutical companies and patient groups have a strong institutional preference for the separation of medicine and are the dominant force in promoting the reform. However, due to its position in the system of institutions and its own characteristics, the influence on policy making is weaker. Central government departments at the core of policy formulation can not form a unified plan because they place too much emphasis on obtaining and safeguarding the interests of their own departments and can not reach a consensus on the arrangement of the pharmaceutical separation system. As a result, the reform of China’s pharmaceutical separation industry has stalled. To promote reform and achieve thorough separation of medicine, we need to coordinate the interests of all groups and build a system platform for each group to achieve an orderly game.